578 Results (Page 2 of 24)
Canada Markets Research Reports
Canada Pharmacy Automation Device Market Analysis
The Canada Pharmacy Automation Device Market was valued at $440 Mn in 2023 and is predicted to grow at a CAGR of 9.9% from 2023 to 2030, to $852 Mn by 2030. Canada Pharmacy Automation Device Market is growing due to Adoption of Electronic Health Records, Reducing Human Errors, and Rising Demand for Pharmaceuticals. The market is primarily dominated by players such as Amerisource Bergen Corporation, Accu-Chart Plus Healthcare Systems, Omnicell, Inc., McKesson Corporation; Pearson Medical Technologies, Baxter; Talyst, LLC, Scriptpro LLC.
Canada Biosensors Market Analysis
The Canada Biosensors Market was valued at $2312 Mn in 2023 and is predicted to grow at a CAGR of 8% from 2023 to 2030, to $3962.4 Mn by 2030. The key drivers of the market include increasing burden of chronic diseases, technological advancements, and growing demand for Point-of-Care (POC) testing. The prominent players of the Canada Biosensors Market are Nicoya Lifesciences, SomaDetect, Biosensors International, Nix Biosensors, Nova Biomedical Corporation, and Abbott Laboratories, among others.
Canada Clinical Nutrition Market Analysis
The Canada Clinical Nutrition Market was valued at $2453.6 Mn in 2023 and is projected to grow at a CAGR of 5.34% from 2023 to 2023, to $3531.5 Mn by 2030. The key drivers of this industry are increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients which has contributed to market growth. The industry is primarily dominated by players such as Vicore Pharma Holding, Cambrooke Therapeutics, Abbott Nutrition, Bayer AG, Nestle among others.
Canada Oculopharyngeal Muscular Dystrophy (OPMD) Market Analysis
Canada Oculopharyngeal Muscular Dystrophy (OPMD) market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for Oculopharyngeal Muscular Dystrophy (OPMD)is growing due to increase spending in research and development activities by pharmaceutical companies, incentives provided by regulatory authorities like orphan drug designations and accelerated approval pathways, patient support and advocacy programmes which help to increase awareness about disease and provide support to patients. Bristol-Myers Squibb, BioMarin, Sarepta Therapeutics, Benitec Biopharma Inc., Bioblast Pharma, PTC Therapeutics, NS Pharma, Nobelpharma Co., Ltd ,Santhera Pharmaceuticals, Pfizer Inc. ,Marathon Pharmaceuticals, Fibrogen, GSK are the key global market players.
Canada Mental Health Apps Market Analysis
The Canada Mental Health Apps Market was valued at $496 Mn in 2023 and is predicted to grow at a CAGR of 15.2% from 2023 to 2030, to $1335.52 Mn by 2030. The key drivers of this industry include rising awareness, advancement in technology, and increasing smartphone penetration. The industry is primarily dominated by players such as Pocketwell, PTSD Coach Canada, Hope, TELUS Health MyCare, and Mindshift among others.
Canada Cardiac Pacemakers Market Analysis
The Canada Cardiac Pacemakers Market was valued at $323.75 Mn in 2023 and is predicted to grow at a CAGR of 3.20% from 2023 to 2030, to $403.62 Mn by 2030. The key drivers of this industry include an aging population, the prevalence of cardiovascular disease, and technological advancements. The industry is primarily dominated by players such as Abbott Laboratories, Biotronik, Boston Scientific, and Medtronic among others.
Canada Clinical Nutrition for Cancer Care Market Analysis
The Canada Clinical Nutrition for Cancer Care Market was valued at $450.4 Mn in 2023 and is predicted to grow at a CAGR of 5.04% from 2023 to 2030, to $635.5 Mn by 2030. The key drivers of the market include the increasing prevalence of cancer, increased awareness and education, and increasing healthcare expenditure. The prominent players of the Canada Clinical Nutrition for Cancer Care Market are Nestlé Health Science, Abbott Nutrition, B. Braun Melsungen AG, Pfizer, and Fresenius Kabi, among others.
Canada Gram-Negative Infection Therapeutics Market Analysis
The Canada Gram-Negative Infection Therapeutics Market was valued at $1190.08 Mn in 2023 and is predicted to grow at a CAGR of 5.9% from 2023 to 2030 to $1777.5 Mn by 2030. Market dynamics are driven by the increasing incidence of infections, unmet medical needs, and favourable government initiatives. Leading companies in this market include AstraZeneca and Johnson & Johnson, among others.
Canada Home Infusion Therapy Market
The Canada Home Infusion Therapy Market was valued at $2876.8 Mn in 2023 and is predicted to grow at a CAGR of 8.1% from 2023 to 2030, to $4962.4 Mn by 2030. The key drivers of the market include rising prevalence of chronic diseases, expanding geriatric population, and technological advancements. The prominent players of the Canada Home Infusion Therapy Market are Option Care Health, Baxter International, ICU Medical (Smiths Medical), Becton, Dickinson and Company (BD), and Fresenius Kabi, among others.
Canada Hepatitis A Therapeutics Market Analysis
The Canada Hepatitis A Therapeutics Market valued at $58.98 Mn in 2023, projected to reach $68.68 Mn by 2030 with a CAGR of 2.2%. Key industry drivers encompass increasing prevalence, inadequate personal hygiene and sanitation facilities, and government initiatives. Leading companies in this sector include GlaxoSmithKline (GSK) and Sanofi, among others.
Canada X-Linked Myotubular Myopathy (XLMTM) Drugs Market Analysis
Canada X-Linked Myotubular Myopathy (XLMTM) Drugs market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. The market for X-Linked Myotubular Myopathy (XLMTM) Drugs is growing rapidly as a result of unmet medical need for therapies of X-Linked Myotubular Myopathy (XLMTM) disease, advancements in gene therapy, Growing Awareness and Patient Advocacy about the disease, Increased Research and Collaboration between research organizations and pharmaceutical companies, supportive regulatory environments, Technological Advancements in gene sequencing and biomarker identification. Novartis Gene Therapies, Avrobio, Axovant Gene Therapies, Sarepta Therapeutics, Amicus Therapeutics, Sanofi Genzyme, Pfizer, Audentes Therapeutics are the key market players operating in global X-Linked Myotubular Myopathy (XLMTM) Drugs market.
Canada Diabetes Therapeutics Market Analysis
This report presents a strategic analysis of the Canada Diabetes Therapeutics Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Canada Diabetes Therapeutics Market, offering unmatched value, accuracy and expert insights.
Canada Chronic Inflammatory Demyelinating Polyneuritis Therapeutics Market Analysis
Canada Chronic Inflammatory Demyelinating Polyneuritis Therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. A acquired immune-mediated neuropathy that affects peripheral nerves and nerve roots, chronic inflammatory demyelinating polyneuropathy (CIDP; also known as chronic inflammatory demyelinating polyradiculoneuropathy) is characterised by a progressive or relapsing-remitting course of symmetric weakness of the proximal and distal muscles. Growing government spending and disease awareness have been the market's main drivers for Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics. Bio products laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Octapharma, Shire, Kedrion SPA, Misubishi Tanabe Pharma Corporation, CSL Behring, and Teijin Pharma Ltd. are global firms in the Chronic Inflammatory Demyelinating Polyneuritis (CIDP) Therapeutics market.
Canada Fibrodysplasia Ossificans Progressiva (FOP) Therapeutics Market Analysis
Canada Fibrodysplasia Ossificans Progressiva Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. An estimated 1.36 per Mn persons are believed to have the ultra-rare condition fibrodysplasia osseous progressiva, which affects about 900 people worldwide. The market for Fibrodysplasia Ossificans Progressiva Drugs is expanding as a result of growing incidence and prevalence of fibrodysplasia ossificans progressiva, increase in the number of R&D activities, increase in Partnerships and Collaborations between market players. Pfizer Inc., AstraZeneca, Limited, Regeneron Pharmaceuticals, Inc, Clementia Pharmaceuticals, Novartis are the top key market players operating in the global Fibrodysplasia Ossificans Progressiva Therapeutics Market.
Canada Women Health Diagnostic Market Analysis
This report presents a strategic analysis of the Canada Women Health Diagnostic Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Canada Women Health Diagnostic Market, offering unmatched value, accuracy and expert insights.
Canada Genomics Market Analysis
The Canada Genomics market was valued at $2,612 Mn in 2023 and is predicted to grow at a CAGR of 16.5% from 2023 to 2030, to $7,607.7 Mn by 2030. The key drivers of the market include the increasing applications of genomics, need for advancements in cancer treatments, increasing trend of personalized medicines, and increased government initiatives in genomics projects. The prominent players of the Canada genomics market are Deep Genomics, Genome BC, Ontario Genomics, Medicago, TheraCell Technologies, Oxford Nanopore Technologies, Illumina, Thermo Fisher Scientific, Danaher Corporation, Qiagen N.V., and Hoffmann-La Roche, among others.
Canada Mucopolysaccharidosis I (MPS-I) Drugs Market Analysis
Canada Mucopolysaccharidosis I (MPS-I) Drugs Market is projected to grow from $0.2 Mn in 2022 to $0.31 Mn by 2030, registering a CAGR of 5.9% during the forecast period of 2023 ? 2030. Rising consumer awareness, new drug approvals, enticing reimbursement plans, an established healthcare system, and the presence of sizable market competitors all drive the market for treating Mucopolysaccharidosis I. Major global players in Mucopolysaccharidosis I (MPS-I) Drugs Market are Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Drugs, Abeona Drugs, Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Drugs, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Canada Pseudomonas Aeruginosa Infection Therapeutics Market Analysis
Canada Pseudomonas Aeruginosa Infection Therapeutics Market is projected to grow from $0.11 Bn in 2022 to $0.17 Bn by 2030, registering a CAGR of 5.7% during the forecast period of 2022-2030. Industry income is expected to increase as a result of increased pseudomonas aeruginosa infections, an ageing population, future innovative antibiotic formulations, an increase in patients, and greater public awareness of the infection. Major global players in Pseudomonas Aeruginosa Infection Therapeutics Market are Allergan, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc, Merck & Co.
Canada Lysosomal Storage Disease Therapeutics Market Analysis
Canada lysosomal storage disease therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The rise in lysosomal diseases, greater public awareness of unusual lysosomal storage disorders, increased research and development for diagnostics, and increased drug development for treating lysosomal diseases are the main drivers impacting the market for lysosomal storage disease treatments. Major global players in this market are Pfizer Inc, Takeda Pharmaceutical Company Limited (Shire Plc), Sanofi (Genzyme Corporation), BioMarin, Johnson & Johnson (Actelion Pharmaceuticals Ltd), Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, Sigilon Therapeutics, Inc, and Orphazyme A/S are some of the companies that participate in this industry.
Canada Lymphoma Therapeutics Market Analysis
Canada's Lymphoma Therapeutics Market was valued at $555.2 Mn in 2023 and is predicted to grow at a CAGR of 8.30% from 2023 to 2030, to $970.2 Mn by 2030. The key drivers of this industry include a high lymphoma cancer incidence rate, advancements in t-cell lymphoma-specific therapies, and rising healthcare expenditure. The industry is primarily dominated by AbbVie Inc., Bristol-Myers Squibb Co., Celgene Corporation, Johnson & Johnson, Novartis AG, Pfizer Inc., and Roche Holding AG. among others.
Canada Kidney Cancer Therapeutics Market Analysis
The Canada Kidney Cancer Therapeutics Market was valued at $503.20 Mn in 2023 and is predicted to grow at a CAGR of 4.86% from 2023 to 2030, to $701.47 Mn by 2030. The key drivers of this industry include the rising incidence of kidney cancer, advancements in treatment options, and government support. The industry is primarily dominated by players such as AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, Merck, Bayer, Amgen, Roche, Abbott and Eisai Limited.
Canada Myeloproliferative Disorders (MPD) Therapeutics Market Analysis
Canada Myeloproliferative Disorders (MPD) therapeutics market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The market for drugs to treat myeloproliferative disorders is expected to expand as a result of the rising prevalence of the different myeloproliferative disorders, the existence of promising pipeline products, regular product approvals, and rising R&D expenditures on the creation of new drugs for the MPD Treatment market. Major global players in this market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd, Bristol Myers Squibb Company, GSK Plc, Bayer AG, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International Gmbh, Sanofi.
Canada Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
Canada's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 7.1% from 2022 to 2030 and will reach $2.52 Bn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate, a result of government initiatives. The market is segmented by Drug class and by distribution channel. Some key players in this market are Abbott Laboratories, Adamis Pharmaceuticals Corporation, Almirall, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva Canada Limited, and others.
Canada COVID-19 Clinical Trials Market Analysis
This report presents a strategic analysis of the Canadian COVID-19 Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the Canadian COVID-19 Clinical Trials Market, offering unmatched value, accuracy, and expert insights.
Canada Growth Hormone Deficiency Clinical Trials Market Analysis
This report presents a strategic analysis of the Canada Growth Hormone Deficiency Clinical Trials Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the Canada Growth Hormone Deficiency Clinical Trials Market, offering unmatched value, accuracy and expert insights.
